Evidence map›Paper›PMID 42294902›Full record

ArticleThe Journal of clinical investigation2026

Inactive β1-integrin acts as a junctional scaffold for angiopoietin/TIE2/FOXO1 signaling.

Tuomas Sipilä, Srinivas Kumar Ponna, Abhinandan Venkatesha Murthy, Anne Pink, Giray Enkavi, Shraman Kumar Bohra, Klaudia Lewna, Keerthana Ganesh, Qina Liu, Mirka Korhonen and 6 more

Abstract read
In one paragraph

Article in The Journal of clinical investigation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Tuomas SipiläTranslational Cancer Medicine Program, Research Programs Unit.
Srinivas Kumar PonnaTranslational Cancer Medicine Program, Research Programs Unit.
Abhinandan Venkatesha MurthyTranslational Cancer Medicine Program, Research Programs Unit.
Anne PinkTranslational Cancer Medicine Program, Research Programs Unit.
Giray EnkaviDepartment of Physics, and.
Shraman Kumar BohraTranslational Cancer Medicine Program, Research Programs Unit.
Klaudia LewnaTranslational Cancer Medicine Program, Research Programs Unit.
Keerthana GaneshTranslational Cancer Medicine Program, Research Programs Unit.
Qina LiuTranslational Cancer Medicine Program, Research Programs Unit.
Mirka KorhonenTranslational Cancer Medicine Program, Research Programs Unit.
Tommi KajanderInstitute of Biotechnology, University of Helsinki, Helsinki, Finland.
Michael PotenteAngiogenesis & Metabolism Laboratory, Center of Vascular Biomedicine, Berlin Institute of Health at Charité - Universitätsmedizin Berlin, Berlin, Germany & Max Delbrück Center for Molecular Medicine in the Helmholtz Association, Berlin, Germany.
Johanna IvaskaTurku Bioscience Centre, University of Turku and Åbo Akademi University, Turku, Finland.
Ilpo VattulainenDepartment of Physics, and.
Veli-Matti LeppänenTurku Bioscience Centre, University of Turku and Åbo Akademi University, Turku, Finland.
Pipsa SaharinenTranslational Cancer Medicine Program, Research Programs Unit.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The blood and lymphatic vascular systems are regulated by angiopoietin (ANGPT) growth factors, which signal via endothelial TIE receptor tyrosine kinases and integrins. However, mechanistic understanding of how these receptors crosstalk is limited. Here, we show how β1-integrin inactivation regulates endothelial ANGPT/TIE2 signaling. By integrating biophysical analyses, X-ray crystallography, size-exclusion chromatography-small-angle X-ray scattering and atomistic molecular dynamics simulations, we show that ANGPT2 binds through its asymmetrically positioned C-terminal fibrinogen-like domains to both TIE2 and α5β1-integrin, forming a trimeric complex compatible with the inactive α5β1-integrin conformation. Inactive β1-integrin colocalizes with ANGPT-induced TIE2 in cell-cell junctions and stabilizing β1-integrin in its inactive state enhances junctional TIE2 accumulation and promotes nuclear exclusion of the TIE2 transcriptional effector FOXO1 in cultured endothelial cells. Endothelial-specific β1-integrin deletion in adult mice reduces venous TIE2 phosphorylation, whereas endotoxemia diminishes junctional β1-integrin along with decreased phosphorylated TIE2. In contrast, without TIE2, ANGPT2 uniquely engages active β1-integrin, via its N-terminal superclustering domain. Altogether, our results provide structural and mechanistic evidence of ANGPT signaling via α5β1-integrin and support a model in which inactive α5β1-integrin acts as a junctional scaffold for ANGPT/TIE2/FOXO1 signaling, explaining how integrin conformational switching spatially organizes growth factor signaling in the endothelium.

Indexed as

Angiopoietin-2Forkhead Box Protein O1Integrin beta1Intercellular JunctionsReceptor, TIE-2Signal TransductionAnimalsHumansIntegrin alpha5beta1MiceMice, KnockoutAngiopoietin-2ANGPT2 protein, humanAngpt2 protein, mouseForkhead Box Protein O1FOXO1 protein, humanFoxo1 protein, mouseIntegrin alpha5beta1Integrin beta1Itgb1 protein, mouseReceptor, TIE-2TEK protein, humanTek protein, mouseAngiogenesisCell biologyGrowth factorsIntegrinsVascular biology

Identifiers

PMID42294902
PMCPMC13262729

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.